Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner

Hiroya Kobayashi, Toshihiro Nagato, Keisuke Sato, Naoko Aoki, Shoji Kimura, Masamoto Murakami, Hajime Iizuka, Makoto Azumi, Hidehiro Kakizaki, Masatoshi Tateno, Esteban Celis

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The six-transmembrane epithelial antigen of prostate (STEAP) protein is an attractive candidate for T cell-based immunotherapy because it is overexpressed in prostate cancer and various other tumor types. Several peptide epitopes capable of stimulating CTLs that killed STEAP-expressing tumor cells have been described. Our goal was the identification of helper T lymphocyte (HTL) epitopes of STEAP for the optimization of T cell-based immunotherapies against STEAP-expressing malignancies. Candidate HTL epitopes for STEAP were predicted using in silico algorithms for HLA class II-binding peptides and were tested for their ability to elicit HTL responses by in vitro peptide vaccination of CD4 T lymphocytes from healthy individuals and prostate cancer patients. Two peptides (STEAP102-116 and STEAP192-206) were effective in stimulating in vitro antitumor HTL responses in both normal individuals and prostate cancer patients. Notably, both STEAP HTL peptides behaved as promiscuous T-cell epitopes because they stimulated T cells in the context of more than one MHC class II allele. These newly described STEAP HTL epitopes could be of value for the design and optimization of T cell-based immunotherapy against STEAP-expressing tumors.

Original languageEnglish (US)
Pages (from-to)5498-5504
Number of pages7
JournalCancer Research
Volume67
Issue number11
DOIs
StatePublished - Jun 1 2007
Externally publishedYes

Fingerprint

HLA Antigens
Helper-Inducer T-Lymphocytes
Prostate
Melanoma
Antigens
T-Lymphocyte Epitopes
Neoplasms
T-Lymphocytes
Peptides
Immunotherapy
Prostatic Neoplasms
Epithelial Cell Adhesion Molecule
Computer Simulation
Epitopes
Vaccination
Alleles

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner. / Kobayashi, Hiroya; Nagato, Toshihiro; Sato, Keisuke; Aoki, Naoko; Kimura, Shoji; Murakami, Masamoto; Iizuka, Hajime; Azumi, Makoto; Kakizaki, Hidehiro; Tateno, Masatoshi; Celis, Esteban.

In: Cancer Research, Vol. 67, No. 11, 01.06.2007, p. 5498-5504.

Research output: Contribution to journalArticle

Kobayashi, Hiroya ; Nagato, Toshihiro ; Sato, Keisuke ; Aoki, Naoko ; Kimura, Shoji ; Murakami, Masamoto ; Iizuka, Hajime ; Azumi, Makoto ; Kakizaki, Hidehiro ; Tateno, Masatoshi ; Celis, Esteban. / Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner. In: Cancer Research. 2007 ; Vol. 67, No. 11. pp. 5498-5504.
@article{c250e268ddb24bed8f94949c21d97416,
title = "Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner",
abstract = "The six-transmembrane epithelial antigen of prostate (STEAP) protein is an attractive candidate for T cell-based immunotherapy because it is overexpressed in prostate cancer and various other tumor types. Several peptide epitopes capable of stimulating CTLs that killed STEAP-expressing tumor cells have been described. Our goal was the identification of helper T lymphocyte (HTL) epitopes of STEAP for the optimization of T cell-based immunotherapies against STEAP-expressing malignancies. Candidate HTL epitopes for STEAP were predicted using in silico algorithms for HLA class II-binding peptides and were tested for their ability to elicit HTL responses by in vitro peptide vaccination of CD4 T lymphocytes from healthy individuals and prostate cancer patients. Two peptides (STEAP102-116 and STEAP192-206) were effective in stimulating in vitro antitumor HTL responses in both normal individuals and prostate cancer patients. Notably, both STEAP HTL peptides behaved as promiscuous T-cell epitopes because they stimulated T cells in the context of more than one MHC class II allele. These newly described STEAP HTL epitopes could be of value for the design and optimization of T cell-based immunotherapy against STEAP-expressing tumors.",
author = "Hiroya Kobayashi and Toshihiro Nagato and Keisuke Sato and Naoko Aoki and Shoji Kimura and Masamoto Murakami and Hajime Iizuka and Makoto Azumi and Hidehiro Kakizaki and Masatoshi Tateno and Esteban Celis",
year = "2007",
month = "6",
day = "1",
doi = "10.1158/0008-5472.CAN-07-0304",
language = "English (US)",
volume = "67",
pages = "5498--5504",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner

AU - Kobayashi, Hiroya

AU - Nagato, Toshihiro

AU - Sato, Keisuke

AU - Aoki, Naoko

AU - Kimura, Shoji

AU - Murakami, Masamoto

AU - Iizuka, Hajime

AU - Azumi, Makoto

AU - Kakizaki, Hidehiro

AU - Tateno, Masatoshi

AU - Celis, Esteban

PY - 2007/6/1

Y1 - 2007/6/1

N2 - The six-transmembrane epithelial antigen of prostate (STEAP) protein is an attractive candidate for T cell-based immunotherapy because it is overexpressed in prostate cancer and various other tumor types. Several peptide epitopes capable of stimulating CTLs that killed STEAP-expressing tumor cells have been described. Our goal was the identification of helper T lymphocyte (HTL) epitopes of STEAP for the optimization of T cell-based immunotherapies against STEAP-expressing malignancies. Candidate HTL epitopes for STEAP were predicted using in silico algorithms for HLA class II-binding peptides and were tested for their ability to elicit HTL responses by in vitro peptide vaccination of CD4 T lymphocytes from healthy individuals and prostate cancer patients. Two peptides (STEAP102-116 and STEAP192-206) were effective in stimulating in vitro antitumor HTL responses in both normal individuals and prostate cancer patients. Notably, both STEAP HTL peptides behaved as promiscuous T-cell epitopes because they stimulated T cells in the context of more than one MHC class II allele. These newly described STEAP HTL epitopes could be of value for the design and optimization of T cell-based immunotherapy against STEAP-expressing tumors.

AB - The six-transmembrane epithelial antigen of prostate (STEAP) protein is an attractive candidate for T cell-based immunotherapy because it is overexpressed in prostate cancer and various other tumor types. Several peptide epitopes capable of stimulating CTLs that killed STEAP-expressing tumor cells have been described. Our goal was the identification of helper T lymphocyte (HTL) epitopes of STEAP for the optimization of T cell-based immunotherapies against STEAP-expressing malignancies. Candidate HTL epitopes for STEAP were predicted using in silico algorithms for HLA class II-binding peptides and were tested for their ability to elicit HTL responses by in vitro peptide vaccination of CD4 T lymphocytes from healthy individuals and prostate cancer patients. Two peptides (STEAP102-116 and STEAP192-206) were effective in stimulating in vitro antitumor HTL responses in both normal individuals and prostate cancer patients. Notably, both STEAP HTL peptides behaved as promiscuous T-cell epitopes because they stimulated T cells in the context of more than one MHC class II allele. These newly described STEAP HTL epitopes could be of value for the design and optimization of T cell-based immunotherapy against STEAP-expressing tumors.

UR - http://www.scopus.com/inward/record.url?scp=34347210340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347210340&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-0304

DO - 10.1158/0008-5472.CAN-07-0304

M3 - Article

VL - 67

SP - 5498

EP - 5504

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 11

ER -